open access

Vol 86, No 3 (2015)
ARTICLES
Get Citation

Increase of nuclear expression of metallothionein I/II in neoplastic transformation of the endometrium

Lukasz Jagielski, Michał Jelen, Christopher Kobierzycki, Gizela Jagielska, Radosław Blok
DOI: 10.17772/gp/2060
·
Ginekol Pol 2015;86(3).

open access

Vol 86, No 3 (2015)
ARTICLES

Abstract

Objectives: The aim of our study was to investigate the expression of epidermal growth factor receptor (EGFR), metallothionein (MT) I/II, and Ki-67 antigen in endometrial cancer. We analyzed cytoplasmic (cMT) and nuclear (nMT) metallothionein fractions separately. Moreover, we evaluated the relationships between expressions of the above mentioned proteins and compared them with clinicopathologic data. Material and methods: The study material included paraffin-embedded endometrial cancer samples from 84 patients. The control group consisted of 52 non-neoplastic endometrium samples. Immunohistochemical reactions were performed using monoclonal antibodies against EGFR, MT I/II and Ki-67. Expression intensity of the tested proteins was assessed by computer image analysis software. Chi-square, Spearman’s correlation, Mann-Whitney and Kruskal-Wallis tests were used for statistical analysis with Statistica 8.0 PL. Results: Strong expression of nMT was revealed in endometrial cancer cells in relation to benign hyperplasia (p<0.001) and normal cells (p<0.001) of the endometrium. Statistically significant but weaker expressions in analogous relationships were observed for cMT. Moreover, higher grade of histological malignancy G was positively associated with increased expression of nMT (p=0.009). Conclusions: Expression of nMT remains in distinct correlation with neoplastic transformation of the endometrium and histologic grades. Our results clearly indicate a need for further research on metallothionein expression in tumor cells.

Abstract

Objectives: The aim of our study was to investigate the expression of epidermal growth factor receptor (EGFR), metallothionein (MT) I/II, and Ki-67 antigen in endometrial cancer. We analyzed cytoplasmic (cMT) and nuclear (nMT) metallothionein fractions separately. Moreover, we evaluated the relationships between expressions of the above mentioned proteins and compared them with clinicopathologic data. Material and methods: The study material included paraffin-embedded endometrial cancer samples from 84 patients. The control group consisted of 52 non-neoplastic endometrium samples. Immunohistochemical reactions were performed using monoclonal antibodies against EGFR, MT I/II and Ki-67. Expression intensity of the tested proteins was assessed by computer image analysis software. Chi-square, Spearman’s correlation, Mann-Whitney and Kruskal-Wallis tests were used for statistical analysis with Statistica 8.0 PL. Results: Strong expression of nMT was revealed in endometrial cancer cells in relation to benign hyperplasia (p<0.001) and normal cells (p<0.001) of the endometrium. Statistically significant but weaker expressions in analogous relationships were observed for cMT. Moreover, higher grade of histological malignancy G was positively associated with increased expression of nMT (p=0.009). Conclusions: Expression of nMT remains in distinct correlation with neoplastic transformation of the endometrium and histologic grades. Our results clearly indicate a need for further research on metallothionein expression in tumor cells.
Get Citation

Keywords

endometrial cancer / epidermal growth factor receptor / EGFR / / metallothionein

About this article
Title

Increase of nuclear expression of metallothionein I/II in neoplastic transformation of the endometrium

Journal

Ginekologia Polska

Issue

Vol 86, No 3 (2015)

DOI

10.17772/gp/2060

Bibliographic record

Ginekol Pol 2015;86(3).

Keywords

endometrial cancer / epidermal growth factor receptor / EGFR / / metallothionein

Authors

Lukasz Jagielski
Michał Jelen
Christopher Kobierzycki
Gizela Jagielska
Radosław Blok

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl